Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia.
Pinelopi GrigoropoulouAnastasios TentolourisIoanna EleftheriadouDimitrios TsilingirisCharalambos VlachopoulosMaria SykaraNikolaos TentolourisPublished in: Diabetes & vascular disease research (2018)
Cardiovascular disease is the leading cause of morbidity and mortality in subjects with type 2 diabetes mellitus. Increased aortic stiffness, assessed with the carotid-femoral pulse wave velocity, is an independent risk factor for cardiovascular disease. Statins reduce effectively cardiovascular disease and mortality in high-risk patients. The aim of this prospective non-randomized, observational study was to examine the impact of treatment with either 10 mg atorvastatin plus diet or diet alone on carotid-femoral pulse wave velocity in subjects with type 2 diabetes mellitus and dyslipidaemia. A total of 79 subjects with type 2 diabetes mellitus and dyslipidaemia were included; 46 subjects were treated with atorvastatin 10 mg daily plus diet and 33 were managed by diet alone for 12 months. Carotid-femoral pulse wave velocity and carotid-radial pulse wave velocity were measured using applanation tonometry. In the atorvastatin-treated group, carotid-femoral pulse wave velocity reduced significantly during the study and there was a trend for reduction in the carotid-radial pulse wave velocity. Total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-reactive protein were reduced only in the atorvastatin-treated participants. No significant changes were found in body mass index, blood pressure, heart rate, diabetes control and high-density lipoprotein cholesterol in either study group. Treatment with low-dose atorvastatin for 12 months improves carotid-femoral pulse wave velocity in subjects with type 2 diabetes mellitus and dyslipidaemia.
Keyphrases
- blood pressure
- cardiovascular disease
- heart rate
- blood flow
- low dose
- physical activity
- hypertensive patients
- body mass index
- type diabetes
- weight loss
- newly diagnosed
- heart rate variability
- end stage renal disease
- cardiovascular events
- high dose
- chronic kidney disease
- aortic valve
- ejection fraction
- insulin resistance
- clinical trial
- prognostic factors
- coronary artery disease
- heart failure
- atrial fibrillation
- left ventricular
- metabolic syndrome
- peritoneal dialysis
- patient reported outcomes
- placebo controlled